CG Oncology CEO granted 271,600 stock options
CG Oncology, Inc. reported that Chief Executive Officer Arthur Kuan received a grant of employee stock options covering 271,600 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
CG Oncology, Inc. reported that Chief Executive Officer Arthur Kuan received a grant of employee stock options covering 271,600 shares of common stock. The options have an exercise price of $67.68 per share and expire on April 14, 2036.
According to the award terms, 1/48th of the shares subject to the option vest monthly following April 15, 2026, as long as Kuan continues to provide services to the company through each vesting date. After this grant, he holds 271,600 derivative securities linked to common stock.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (Right to Buy) | 271,600 | $0.00 | $0.00 |
Footnotes (1)
- F1. 1/48th of the shares subject to the option vest monthly following April 15, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Key Figures
Key Terms
Employee Stock Option financial
exercise price financial
vesting financial
derivative securities financial
expiration date financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CGON CEO Arthur Kuan report on this Form 4?
What is the exercise price of the CGON stock options granted to the CEO?
When do Arthur Kuan’s CGON stock options start vesting and on what schedule?
When do the CGON stock options granted to the CEO expire if unexercised?
AI-generated analysis. How Rhea-AI works. Not financial advice.